Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals REGN
$ 732.87 -0.62%

Annual report 2025
added 02-04-2026

report update icon

Regeneron Pharmaceuticals Financial Statements 2011-2026 | REGN

Annual Financial Statements Regeneron Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

81.3 B 77.7 B 100 B 83.6 B 66.8 B 52 B 36.7 B 45.3 B 40.4 B 36.1 B 43.3 B 41.9 B 28.7 B 16.5 B 8.05 B

Shares

105 M 108 M 107 M 107 M 106 M 108 M 109 M 108 M 106 M 105 M 103 M 101 M 97.9 M 94.7 M 90.6 M

Historical Prices

777 720 939 781 632 483 375 374 376 367 543 410 275 171 55.4

Net Income

4.5 B 4.41 B 3.95 B 4.34 B 8.08 B 3.51 B 2.12 B 2.44 B 1.2 B 896 M 636 M 348 M 424 M 750 M -222 M

Revenue

14.3 B 14.2 B 13.1 B 12.2 B 16.1 B 8.5 B 7.86 B 6.71 B 5.87 B 4.86 B 4.1 B 2.82 B 2.1 B 1.38 B 446 M

Cost of Revenue

- - - - - - 403 M 238 M - - - - - - -

Gross Profit

- - - - - - 7.08 B 6.28 B 5.48 B 4.56 B 3.71 B 2.61 B 1.95 B 1.29 B 442 M

Operating Income

3.58 B 3.99 B 4.05 B 4.74 B 8.95 B 3.58 B 2.21 B 2.53 B 2.08 B 1.33 B 1.25 B 824 M 743 M 458 M -205 M

Interest Expense

1.7 B 844 M 225 M 179 M 57.3 M 56.9 M 30.2 M 28.2 M 25.1 M 7.2 M 14.2 M 37.4 M 46.4 M 45.3 M 21.3 M

EBITDA

4.12 B 4.47 B 4.47 B 5.08 B 9.23 B 3.81 B 2.42 B 2.68 B 2.23 B 1.44 B 1.33 B 891 M 801 M 495 M -174 M

Operating Expenses

- - - - - - 4.87 B 3.74 B 3.4 B 3.23 B 2.46 B 1.78 B 1.19 B 836 M 647 M

General and Administrative Expenses

2.7 B 2.95 B 2.63 B 2.12 B 1.82 B 1.35 B 1.83 B 1.56 B 1.32 B 1.18 B 839 M 505 M 329 M 211 M 117 M

All numbers in USD currency

Quarterly Income Statement Regeneron Pharmaceuticals

2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

105 M 107 M 108 M 108 M 108 M 106 M 107 M 107 M - 107 M 108 M 107 M - 106 M 105 M 105 M - 106 M 110 M 110 M - 109 M 109 M 109 M - 108 M 108 M 108 M - 107 M 106 M 106 M - 105 M 105 M 104 M - 103 M 103 M 102 M - 101 M 100 M 98.7 M - 98.2 M 97.7 M 96.9 M - 95 M 94.6 M 93.4 M 90.7 M 91 M 90.4 M 89.2 M

Net Income

1.39 B 809 M 1.34 B 1.43 B 722 M 1.01 B 968 M 818 M - 1.32 B 852 M 974 M - 1.63 B 3.1 B 1.12 B 1.15 B 842 M 897 M 625 M 792 M 670 M 193 M 461 M 820 M 595 M 551 M 478 M 174 M 388 M 388 M 249 M 253 M 265 M 196 M 181 M 155 M 210 M 195 M 76 M 90.1 M 90.1 M 90.1 M 90.1 M 96.8 M 141 M 87.4 M 98.9 M 470 M 191 M 76.7 M 11.7 M -53.4 M -62.4 M -62.5 M -43.4 M

Revenue

3.68 B 3.03 B 3.72 B 3.55 B 3.14 B 3.36 B 3.16 B 3.16 B - 2.94 B 2.86 B 2.97 B - 3.45 B 5.14 B 2.53 B 2.42 B 2.29 B 1.95 B 1.83 B 1.86 B 1.74 B 1.58 B 1.37 B 1.93 B 1.66 B 1.61 B 1.51 B 1.58 B 1.5 B 1.47 B 1.32 B 1.23 B 1.22 B 1.21 B 1.2 B 1.1 B 1.14 B 999 M 870 M 802 M 726 M 666 M 626 M 610 M 597 M 458 M 440 M 415 M 428 M 304 M 232 M 123 M 103 M 108 M 112 M

Operating Income

1.08 B 592 M 1.18 B 1.07 B 751 M 1.11 B 1.02 B 947 M - 1.22 B 1.11 B 1.26 B - 1.85 B 3.35 B 1.11 B - 1.05 B 656 M 700 M - 738 M 316 M 480 M - 627 M 622 M 567 M - 560 M 550 M 431 M - 363 M 292 M 329 M - 392 M 345 M 284 M 216 M 824 M 216 M 216 M - 237 M 158 M 153 M - 202 M 87.5 M 22.2 M - -58.5 M -60.3 M -41 M

Interest Expense

443 M 322 M 327 M 573 M -34.6 M 17.6 M 85.3 M 18 M - 15.3 M 13.1 M 13.6 M - 14.2 M 14.4 M 14.6 M - 26.3 M 9.7 M 6.1 M - 7.8 M 8 M 7.7 M - 7.4 M 6.9 M 6.4 M - 6.18 M 5.4 M 7.5 M - 3.58 M 1.88 M 3.48 M - 1.72 M 2.75 M 6.17 M - 9.23 M 10.2 M 11.6 M - 11.7 M 11.4 M 11.7 M - 11.4 M 11.2 M 11.2 M - 4.06 M 4.05 M 3.72 M

EBITDA

- 719 M - - 866 M - - 1.05 B - 1.46 B 1.11 B 1.33 B - 2.06 B 3.35 B 1.18 B - 1.23 B 771 M 756 M - 894 M 419 M 531 M - 732 M 692 M 604 M - 671 M 624 M 469 M - 439 M 340 M 352 M - 444 M 376 M 300 M 216 M 862 M 240 M 227 M - 267 M 177 M 162 M - 230 M 105 M 30.6 M - -35.3 M -45.4 M -34 M

General and Administrative Expenses

634 M 633 M 714 M 759 M 689 M 640 M 652 M 601 M - 529 M 476 M 450 M - 445 M 415 M 406 M - 327 M 348 M 367 M - 304 M 295 M 291 M - 369 M 365 M 331 M - 307 M 307 M 297 M - 270 M 292 M 290 M - 210 M 175 M 159 M 175 M 519 M 175 M 175 M - 97.6 M 72.5 M 77.3 M - 46.9 M 47.7 M 58.4 M - 32.9 M 24.6 M 23.4 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Regeneron Pharmaceuticals REGN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Regeneron Pharmaceuticals plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Benitec Biopharma Benitec Biopharma
BNTC
$ 10.98 -4.52 % $ 452 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.88 -0.87 % $ 5 B danmarkDanmark
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Milestone Pharmaceuticals Milestone Pharmaceuticals
MIST
$ 1.36 -20.0 % $ 45.5 M canadaCanada
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 15.36 -0.71 % $ 7.59 B niderlandNiderland
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Inventiva S.A. Inventiva S.A.
IVA
$ 5.78 -4.3 % $ 138 M franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 1.21 -3.97 % $ 71.5 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 2.28 -0.44 % $ 1.03 M israelIsrael
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Assembly Biosciences Assembly Biosciences
ASMB
$ 28.46 3.45 % $ 319 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.37 -4.2 % $ 350 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 156.92 -1.23 % $ 7.81 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.4 -3.68 % $ 1.02 B canadaCanada
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.13 -1.64 % $ 10.4 B usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.09 -0.95 % $ 195 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.52 -5.59 % $ 178 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
$ 7.7 -5.87 % $ 1.29 B britainBritain
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.6 -3.8 % $ 115 M usaUSA
Curis Curis
CRIS
$ 0.77 1.89 % $ 4.86 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA